Breaking News

Tweet TWEET

Meet Ms. Joe Ann Bivins, The World's Longest-Supported Recipient Of A Single Heart Assist Device

 Meet Ms. Joe Ann Bivins, The World's Longest-Supported Recipient Of A Single
                             Heart Assist Device

Implanted at University of Michigan Cardiovascular Center, Joe Ann's Heart has
been Supported with the HeartMate II® Left Ventricular Assist Device since
July 2005

PR Newswire

PLEASANTON, Calif. and ANN ARBOR, Mich., March 19, 2013

PLEASANTON, Calif. and ANN ARBOR, Mich., March 19, 2013 /PRNewswire/
--Thoratec Corporation (Nasdaq: THOR), a world leader in device-based
mechanical circulatory support (MCS) therapies to save, support and restore
failing hearts, and the University of Michigan Cardiovascular Center, a leader
in cardiac care, today announced a major milestone in the treatment of heart
failure. Joe Ann Bivins, 68, of Detroit, Michigan, has been supported for the
longest reported period of time on a single heart assist device. The device,
the HeartMate II Left Ventricular Assist Device (LVAD), supplements her
heart's pumping function and allows her to live her life virtually free from
the symptoms of heart failure.

(Photo: http://photos.prnewswire.com/prnh/20130319/SF79560)

Joe Ann was implanted in July 2005 at the University of Michigan, early in the
HeartMate II pivotal clinical trial. Now at nearly eight years of support,
Joe Ann exemplifies the life-improving benefits of LVAD therapy for heart
failure.

According to the American Heart Association, there are approximately 5.8
million individuals living with chronic heart failure in the United States,
many of whom may face a similar decision to the one made by Joe Ann almost
eight years ago. Joe Ann's heart had become too weak to adequately pump
blood, leaving her tired and weak. Francis D. Pagani, M.D., Ph.D., Surgical
Director of the Adult Heart Transplant Program and Director of the Center for
Circulatory Support, told Joe Ann that her condition could improve with the
help of an LVAD, the HeartMate II. Joe Ann elected to have the surgery, and
she now describes her life as being as close to normal as she could imagine.
Today, she sings with her church choir, attends bible study, heads the church
usher board, and stays active and social with her sisters and son by her
side. She also speaks with patients who are considering LVAD treatment for
their heart failure condition, encouraging them to regain the life they once
knew as well.

The fact that Joe Ann is now the longest surviving patient with a heart assist
device came as a surprise to her. Said Bivins: "I didn't even realize my
journey was so significant. I was too busy living my life to the fullest.
It's certainly something special to be given a second chance, and it's even
more of a blessing to know that my story can give others with heart failure
the same hope I have every day, which is to continue to be saved by my
wonderful doctors and nurses, and my HeartMate II."

Joe Ann's experience has been validated by clinical studies, in which
HeartMate II has demonstrated significant improvements in quality of life as
well as reductions in symptoms of heart failure. Joe Ann hopes her story will
encourage people suffering from heart failure to know they have a choice and a
path to a better life.

"Joe Ann is truly a star patient, and her ability to continue to thrive is a
testament to how well LVAD therapy works for patients in heart failure to
alleviate their heart failure symptoms and give them back an improved quality
of life," said Pagani. "We encourage people who are battling heart failure to
speak with their doctors about treatment with an LVAD. Joe Ann is living
proof that this therapy can turn lives around."

HeartMate II is a heart pump called an LVAD, which helps the left side of the
heart to circulate blood to the rest of the body. It is implanted alongside
the heart and supplements the heart's pumping function. The HeartMate II
system also includes accessories that are worn outside the body, including a
controller and batteries that last more than ten hours, allowing patients to
be active.

HeartMate II is the most widely used and extensively studied LVAD in the
world. Featuring innovative design elements, including proprietary textured
surfaces, blood immersed ruby bearings and open flow paths, HeartMate II has
proven to be a highly durable device capable of long-term circulatory
support.[1] In clinical testing, over 80 percent of HeartMate II recipients
became virtually free of heart failure symptoms shortly after implant and
sustained those improvements for the full two-year follow-up period.[2]
Moreover, controlled clinical trials as well as large-scale commercial
experience have demonstrated significant improvement in patients' functional
capacity, with 94 percent of HeartMate II recipients able to perform the
6-minute walk test after six months of support. [3,4] Overall, many patients
report returning to active living, with meaningful improvements in their
quality of life. To date, over 13,000 patients have been implanted with
HeartMate II, including approximately 6,000 currently on support. HeartMate
II is the only continuous-flow LVAD approved by the FDA for both
Bridge-to-Transplantation and Destination Therapy, or permanent support.

Thoratec Corporation and the University of Michigan Cardiovascular Center
encourage heart failure sufferers and their loved ones to learn more about the
choices for treatment and become involved in the treatment plan. The first
step is to speak with a doctor and find out more information about treating
heart failure. 

Learn more about heart failure on the University of Michigan's website. In
addition, the website www.hearthope.com offers helpful information about
locating treatment centers across the country.

About Thoratec

Thoratec is the world leader in mechanical circulatory support with the
broadest product portfolio to treat the full range of clinical needs for
patients suffering from advanced heart failure. The company's products include
the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted
in patients suffering from heart failure. Thoratec also manufactures and
distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is
headquartered in Pleasanton, California. For more information, visit
www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered
trademarks of Thoratec Corporation, and IVAD is a trademark of Thoratec
Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC,
and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

About University of Michigan Health Services

The University of Michigan's commitment to providing advanced cardiovascular
care led to the creation of the University of Michigan Cardiovascular Center.
The 5-level facility opened in 2007 and unites the U-M Health System's
cardiovascular services. The Center includes operating rooms, clinics,
inpatient beds and indoor and outdoor healing gardens. The U-M is the top
ranked heart and heart surgery program among Michigan hospitals. To learn more
visit www.uofmhealth.org/heart.

IMPORTANT INFORMATION

Individual experiences, symptoms, situations, and circumstances may vary.
Please consult your physician or qualified health provider regarding your
condition and appropriate medical treatment.

Indications:The HeartMate II LVAS (Left Ventricular Assist System) is
intended for use as a bridge to transplantation in cardiac transplant
candidates at risk of imminent death from non-reversible left ventricular
failure. The HeartMate II LVAS is also indicated for use in patients with New
York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular
failure who have received optimal medical therapy for at least 45 of the last
60 days, and who are not candidates for cardiac transplantation. The HeartMate
II LVAS is intended for use both inside and outside the hospital.

Contra-Indications:The HeartMate II LVAS is contraindicated in patients who
cannot tolerate or are allergic to anticoagulation therapy.

Common Side Effects:Death, bleeding, cardiac arrhythmia, infection,
respiratory failure, device malfunction, sepsis, right heart failure, renal
failure, stroke, neurologic dysfunction, psychiatric episode, peripheral or
device-related thromboembolic event, hemolysis, hepatic dysfunction,
myocardial infarction.

Many of the preceding paragraphs contain forward-looking statements within the
meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These statements can be identified by the
words, "believes," "views," "expects," "plans," "projects," "hopes," "could,"
"will," "intends," and other similar words. Actual results, events or
performance could differ materially from these forward-looking statements
based on a variety of factors, many of which are beyond Thoratec's control.
Therefore, readers are cautioned not to put undue reliance on these
statements. Investors are cautioned that all such statements involve risks and
uncertainties, including risks related to regulatory approvals, the
development of new products and new markets, the growth of existing markets
for our products, customer and physician acceptance of Thoratec products, the
effects of FDA regulatory requirements, and the effects of competition.
Forward-looking statements contained in this press release should be
considered in light these factors and those factors discussed from time to
time in Thoratec's public reports filed with the Securities and Exchange
Commission, such as those discussed under the heading, "Risk Factors," in
Thoratec's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and other SEC filings. These forward-looking
statements speak only as of the date hereof. Thoratec undertakes no obligation
to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated events.

[1] Reichenbach SH, Masterson KB, Butler KC, Farrar DJ. Negligible bearing
wear in explanted HeartMate II LV ADs following clinical support for up to 4
years. Paper presented at: Proceedings of the Annual Meeting of the
International Society of Rotary Blood Pumps; October 14-15, 2010; Berlin,
Germany.

[2] Park SJ, Milano CA, Tatooles AJ, et al; for the HeartMate II Clinical
Investigators. Outcomes in advanced heart failure patients with left
ventricular assist devices for destination therapy. Circ Heart Fail.
2012;5(2):241-248.

[3] John, Naka, Smedira, et al. Ann Thorac Surg 2011;92:1406-13.

[4] Rogers, Aaronson, Boyle, et al. JACC 2010;55:1826-34.

SOURCE Thoratec Corporation

Website: http://www.thoratec.com
Contact: Karin Pellmann for Thoratec Corporation, +1-646-515-6933,
karin@bentoncommunications.com, or Shantell Kirkendoll for University of
Michigan Health System, +1-734-764-2220, smkirk@med.umich.edu
 
Press spacebar to pause and continue. Press esc to stop.